A double-blind control trial of 40 mg purified brain gangliosides in 40 patients with ALS for six months showed no significant improvement with the drug. An open trial of the same dose of ganglioside for the same period showed measurable improvement in six out of ten patients with a variety of peripheral motor and sensory neuronal degenerations. These studies indicate the need for continuing clinical investigation of the therapeutic usefulness of the purified brain gangliosides.
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)